Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
Autorzy:
Beijert IJ; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. Hentschel AE; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. Bründl J; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Compérat EM; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. Plass K; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. Rodríguez O; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. Subiela Henríquez JD; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. Hernández V; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. de la Peña E; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Alemany I; Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Turturica D; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. Pisano F; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. Soria F; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. Čapoun O; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Bauerová L; Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Pešl M; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Bruins HM; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Radboud University Medical Center, Nijmegen, The Netherlands.; Urology, Zuyderland Medical Center, Sittard/Heerlen, The Netherlands. Runneboom W; Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. Herdegen S; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Breyer J; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Brisuda A; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Calatrava A; Pathology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain. Rubio-Briones J; Urology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain. Seles M; Urology, Medical University of Graz, Graz, Austria. Mannweiler S; Pathology, Medical University of Graz, Graz, Austria. Bosschieter J; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. Kusuma VRM; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. Ashabere D; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. Huebner N; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. Cotte J; Urology, Pitié Salpétrière Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France. Contieri R; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. Claps F; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. Masson-Lecomte A; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Liedberg F; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Cohen D; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. Lunelli L; Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. Cussenot O; Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. El Sheikh S; Pathology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. Volanis D; Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK. Côté JF; Pathology, Pierre et Marie Curie Medical School, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France. Rouprêt M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Pitié Salpétrière Hospital, AP-HP, GRC no 5, ONCOTYPE-URO, Sorbonne University, 75013, Paris, France. Haitel A; Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. Shariat SF; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. Mostafid AH; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK. Nieuwenhuijzen JA; Urology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands. Zigeuner R; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Medical University of Graz, Graz, Austria. Dominguez-Escrig JL; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain. Hacek J; Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Zlotta AR; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Burger M; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Evert M; Pathology, University of Regensburg, Regensburg, Germany. Hulsbergen-van de Kaa CA; Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. van der Heijden AG; Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Kiemeney LALM; Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Soukup V; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic. Molinaro L; Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. Gontero P; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Turin, Italy. Llorente C; Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. Algaba F; Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. Palou J; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain. N'Dow J; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. Ribal MJ; European Association of Urology, Guidelines Office Board, Arnhem, The Netherlands. van der Kwast TH; Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. Babjuk M; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands.; Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.; Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria. Sylvester RJ; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. vanRhijnBWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.v.rhijn@nki.nl.; Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. b.v.rhijn@nki.nl.; European Association of Urology, Non-Muscle Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. b.v.rhijn@nki.nl.; Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. b.v.rhijn@nki.nl.
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
Autorzy:
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Matek C; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Wagner P; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Erber R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Büttner-Herold M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany; Department of Nephropathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wild PJ; Dr. Senckenberg Institute of Pathology (SIP), University Hospital Frankfurt & Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt, Germany. Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Geppert CI; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Compérat EM; Department of Pathology, Medical University of Vienna, Vienna, Austria. Lopez-Beltran A; Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, Cordoba, Spain. Montironi R; Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy. Cheng L; Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA; The Legorreta Cancer Center at Brown University, Providence, RI, USA. van der Kwast T; Laboratory Medicine Program, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Colecchia M; Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy. vanRhijnBWG; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Amin MB; Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA. Netto GJ; Department of Pathology and Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Lehmann J; Urologische Gemeinschaftspraxis Prüner Gang, Kiel, Germany; Department of Urology, Städtisches Krankenhaus Kiel, Kiel, Germany. Stöckle M; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Junker K; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Electronic address: .
Pokaż więcej
Źródło:
European urology oncology [Eur Urol Oncol] 2023 Oct 07. Date of Electronic Publication: 2023 Oct 07.
Electronic health record and research; happy marriage or early divorce?
Autorzy:
Scheltema MJ; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Urology, St. Vincent's Prostate Cancer Research Centre, Darlinghurst, New South Wales, Australia.; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands. vanRhijnBWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Centre, University of Regensburg, Regensburg, Germany.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2023 Oct 07. Date of Electronic Publication: 2023 Oct 07.
Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
Autorzy:
Richters A; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. van Ginkel N; Department of Urology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands. Meijer RP; Department of Oncologic Urology, University Medical Center Utrecht, Utrecht, The Netherlands. Wondergem M; Department of Nuclear Medicine, the Netherlands Cancer Institute, Amsterdam, The Netherlands. Schoots I; Department of Radiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Vis AN; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands. Kiemeney LALM; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. vanRhijnBWG; Department of Urology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany. Witjes JA; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Aben KKH; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.; Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. Mertens LS; Department of Urology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2023 Oct; Vol. 132 (4), pp. 420-427. Date of Electronic Publication: 2023 Jun 15.
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Autorzy:
Stockem CF; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. Mellema JJJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. vanRhijnBWG; Department of Oncological Urology, Netherlands Cancer Institute, Amsterdam, Netherlands. Boellaard TN; Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands. van Montfoort ML; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands. Balduzzi S; Department of Statistics, Netherlands Cancer Institute, Amsterdam, Netherlands. Boormans JL; Department of Oncological Urology, Erasmus Medical Center, Rotterdam, Netherlands. Franckena M; Department of Radiotherapy, Erasmus Medical Center, Rotterdam, Netherlands. Meijer RP; Department of Oncological Urology, University Medical Center (UMC), Utrecht, Netherlands. Robbrecht DGJ; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands. Suelmann BBM; Department of Medical Oncology, University Medical Center (UMC), Utrecht, Netherlands. Schaake EE; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands. van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Pokaż więcej
Źródło:
Frontiers in oncology [Front Oncol] 2023 Aug 29; Vol. 13, pp. 1246603. Date of Electronic Publication: 2023 Aug 29 (Print Publication: 2023).
The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office.
Autorzy:
Devlies W; Department of Urology, UZ Leuven, Leuven, Belgium. de Jong JJ; Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands. Hofmann F; Department of Urology, Umeå University, Luleå, Sweden. Bruins HM; Department of Urology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, The Netherlands. Zuiverloon TCM; Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Smith EJ; EAU Guidelines Office, Arnhem, The Netherlands. Yuan Y; Department of Medicine, McMaster University, Hamilton, ON, Canada. vanRhijnBWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Mostafid H; Department of Urology, Royal Surrey Hospital, Guildford, UK. Santesso N; Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON, Canada. Violette P; Department of Surgery, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada. Omar MI; Academic Urology Unit, University of Aberdeen, Aberdeen, UK. Electronic address: .
Pokaż więcej
Źródło:
European urology focus [Eur Urol Focus] 2023 Aug 24. Date of Electronic Publication: 2023 Aug 24.
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.
Autorzy:
Claps F; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands. Pavan N; Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy. Ongaro L; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. Tierno D; Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. Grassi G; Department of Medical, Surgery and Health Sciences, Hospital of Cattinara, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy. Trombetta C; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. Tulone G; Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy. Simonato A; Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy. Bartoletti R; Department of Translational Research and New Technologies, University of Pisa, 56126 Pisa, Italy. Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands. vanRhijnBWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands. Mir MC; Department of Urology, Hospital Universitario La Ribera, 46600 Valencia, Spain. Scaggiante B; Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
Autorzy:
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Matek C; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Wagner P; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Erber R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Büttner-Herold M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany; Department of Nephropathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wild PJ; Dr. Senckenberg Institute of Pathology (SIP), University Hospital Frankfurt & Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt, Germany. Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Geppert CI; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Compérat EM; Department of Pathology, Medical University of Vienna, Vienna, Austria. Lopez-Beltran A; Unit of Anatomical Pathology, Faculty of Medicine, Cordoba University, Cordoba, Spain. Montironi R; Molecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy. Cheng L; Department of Pathology and Laboratory Medicine, Brown University Warren Alpert Medical School, Providence, RI, USA; The Legorreta Cancer Center at Brown University, Providence, RI, USA. van der Kwast T; Laboratory Medicine Program, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. vanRhijnBWG; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Amin MB; Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Urology, USC Keck School of Medicine, Los Angeles, CA, USA. Netto GJ; Department of Pathology and Laboratory Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Lehmann J; Urologische Gemeinschaftspraxis Prüner Gang, Kiel, Germany; Department of Urology, Städtisches Krankenhaus Kiel, Kiel, Germany. Stöckle M; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Junker K; Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany. Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany; Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. Electronic address: .
Pokaż więcej
Źródło:
European urology oncology [Eur Urol Oncol] 2023 Aug 08. Date of Electronic Publication: 2023 Aug 08.
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Autorzy:
Claps F; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. van de Kamp MW; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Mayr R; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. Bostrom PJ; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.; Department of Urology, Turku University Hospital and University of Turku, Turku, Finland. Shariat SF; Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA.; Department of Urology, Weill Cornell Medical College, New York, NY, USA.; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Hippe K; Department of Pathology, University Medical Center - Regensburg, Regensburg, Germany. Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. Neuzillet Y; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France. Sanders J; Core Facility Molecular Pathology & Biobank, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Otto W; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Jewett MAS; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. Stöhr R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. Zlotta AR; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. Trombetta C; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Burger M; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. Soorojebally Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France. Wullich B; Department of Urology & Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. Bartoletti R; Unit of Urology, Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy. Radvanyi F; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France. Pavan N; Urological Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. Sirab N; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France. Mir MC; Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain. Pouessel D; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.; Department of Medical Oncology, Claudius Regaud Institute, Toulouse University Cancer Center (IUCT) Oncopole, Toulouse, France. van der Kwast TH; Department of Pathology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada. Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen/Nurnberg, Erlangen, Germany. Lotan Y; Department of Urology, University of Texas Southwestern Medical center, Dallas, TX, USA. Bussani R; Department of Pathology, University of Trieste, Trieste, Italy. Allory Y; Institut Curie, CNRS, UMR144, Molecular Oncology Team, PSL Research University, Paris, France.; Department of Pathology, Institut Curie, Paris, France. vanRhijnBWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.; Department of Surgery (Urology) and Surgical Oncology, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło:
BJU international [BJU Int] 2023 Aug; Vol. 132 (2), pp. 170-180. Date of Electronic Publication: 2023 Feb 20.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
